Skip to content

Feasibility and effect of prehabilitation program

Feasibility and effect of prehabilitation program - Feasibility and effect of prehabilitation program

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000041772
Enrollment
68
Registered
2020-09-13
Start date
2020-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

prehabilitation None

Sponsors

Nara Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients aged 65 and over 2) Lung cancer patients 3) Patients undergoing lobectomy with thoracoscopic assistance (with or without lymph node dissection 4) Patients who can secure a period of 21 days or more from the decision to surgery

Exclusion criteria

Exclusion criteria: 1) Patients who do not agree 2) Patients with stage III and IV (% FEV1 less than 50%) chronic obstructive pulmonary disease 3) Patients undergoing home oxygen therapy 4) Patients with manual muscle strength measurement of 2 or less 5) Patients undergoing dialysis 6) Patients visiting a psychiatric clinic 7) Patients with inborn errors of metabolism 8) Patients with problems eating and swallowing 9) Patients who meet the following cancer rehabilitation discontinuation criteria 1. Blood findings: hemoglobin 7.5 g / dl or less, platelets 50,000 / ul or less, white blood cells 3,000 ul or less 2. Findings of metastasis of long bones with invasion of 50% or more of the bone cortex, bone erosion toward the center of the bone, lesions of 3 cm or more of the femur, etc. 3. Compression of cavities, blood vessels, and spinal cord 4. Exudate retention in the pleura, peritoneum, and retroperitoneum due to pain, dyspnea, and restricted movement 5. Central nervous system dysfunction, impaired consciousness, increased intracranial pressure 6. Low / hyperkalemia, low / hypernatremia, low / hypercalcemia 7. Orthostatic hypotension, hypertension of 160/100 mmHg or higher Tachycardia of 8.110 / min or more, ventricular arrhythmia

Design outcomes

Primary

MeasureTime frame
6MWT WHODAS QOR40

Countries

Japan

Contacts

Public ContactMitsuru Ida

Nara Medical University Anesthesiology

nwnh0131@yahoo.co.jp09079627114

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026